for Journals by Title or ISSN
for Articles by Keywords
help
  Subjects -> BIOLOGY (Total: 3126 journals)
    - BIOCHEMISTRY (240 journals)
    - BIOENGINEERING (119 journals)
    - BIOLOGY (1490 journals)
    - BIOPHYSICS (47 journals)
    - BIOTECHNOLOGY (236 journals)
    - BOTANY (228 journals)
    - CYTOLOGY AND HISTOLOGY (30 journals)
    - ENTOMOLOGY (69 journals)
    - GENETICS (163 journals)
    - MICROBIOLOGY (258 journals)
    - MICROSCOPY (10 journals)
    - ORNITHOLOGY (26 journals)
    - PHYSIOLOGY (73 journals)
    - ZOOLOGY (137 journals)

BIOTECHNOLOGY (236 journals)                  1 2 | Last

Showing 1 - 200 of 239 Journals sorted alphabetically
3 Biotech     Open Access   (Followers: 8)
Advanced Biomedical Research     Open Access  
Advances in Bioscience and Biotechnology     Open Access   (Followers: 16)
Advances in Genetic Engineering & Biotechnology     Hybrid Journal   (Followers: 7)
Advances in Regenerative Medicine     Open Access   (Followers: 2)
African Journal of Biotechnology     Open Access   (Followers: 6)
Algal Research     Partially Free   (Followers: 11)
American Journal of Biochemistry and Biotechnology     Open Access   (Followers: 67)
American Journal of Bioinformatics Research     Open Access   (Followers: 7)
American Journal of Polymer Science     Open Access   (Followers: 32)
Anadolu University Journal of Science and Technology : C Life Sciences and Biotechnology     Open Access  
Animal Biotechnology     Hybrid Journal   (Followers: 8)
Annales des Sciences Agronomiques     Full-text available via subscription  
Applied Biochemistry and Biotechnology     Hybrid Journal   (Followers: 43)
Applied Biosafety     Hybrid Journal  
Applied Food Biotechnology     Open Access   (Followers: 3)
Applied Microbiology and Biotechnology     Hybrid Journal   (Followers: 64)
Applied Mycology and Biotechnology     Full-text available via subscription   (Followers: 4)
Arthroplasty Today     Open Access   (Followers: 1)
Artificial Cells, Nanomedicine and Biotechnology     Hybrid Journal   (Followers: 1)
Asia Pacific Biotech News     Hybrid Journal   (Followers: 2)
Asian Journal of Biotechnology     Open Access   (Followers: 9)
Asian Pacific Journal of Tropical Biomedicine     Open Access   (Followers: 2)
Australasian Biotechnology     Full-text available via subscription   (Followers: 1)
Banat's Journal of Biotechnology     Open Access  
BBR : Biochemistry and Biotechnology Reports     Open Access   (Followers: 5)
Beitr?ge zur Tabakforschung International/Contributions to Tobacco Research     Open Access   (Followers: 2)
Bio-Algorithms and Med-Systems     Hybrid Journal   (Followers: 2)
Bio-Research     Full-text available via subscription   (Followers: 3)
Bioactive Materials     Open Access   (Followers: 1)
Biocatalysis and Agricultural Biotechnology     Hybrid Journal   (Followers: 4)
Biocybernetics and Biological Engineering     Full-text available via subscription   (Followers: 5)
Bioethics UPdate     Hybrid Journal   (Followers: 1)
Biofuels     Hybrid Journal   (Followers: 11)
Biofuels Engineering     Open Access   (Followers: 1)
Biological & Pharmaceutical Bulletin     Full-text available via subscription   (Followers: 4)
Biological Cybernetics     Hybrid Journal   (Followers: 10)
Biomarkers and Genomic Medicine     Open Access   (Followers: 3)
Biomarkers in Drug Development     Partially Free   (Followers: 1)
Biomaterials Research     Open Access   (Followers: 4)
BioMed Research International     Open Access   (Followers: 4)
Biomédica     Open Access  
Biomedical and Biotechnology Research Journal     Open Access  
Biomedical Engineering Research     Open Access   (Followers: 6)
Biomedical Glasses     Open Access  
Biomedical Reports     Full-text available via subscription  
BioMedicine     Open Access  
Biomedika     Open Access  
Bioprinting     Hybrid Journal   (Followers: 1)
Bioresource Technology Reports     Hybrid Journal   (Followers: 1)
Bioscience, Biotechnology, and Biochemistry     Hybrid Journal   (Followers: 21)
Biosensors Journal     Open Access  
Biosimilars     Open Access   (Followers: 1)
Biosurface and Biotribology     Open Access  
Biotechnic and Histochemistry     Hybrid Journal   (Followers: 1)
BioTechniques : The International Journal of Life Science Methods     Full-text available via subscription   (Followers: 28)
Biotechnologia Acta     Open Access   (Followers: 1)
Biotechnologie, Agronomie, Société et Environnement     Open Access   (Followers: 2)
Biotechnology     Open Access   (Followers: 6)
Biotechnology & Biotechnological Equipment     Open Access   (Followers: 4)
Biotechnology Advances     Hybrid Journal   (Followers: 33)
Biotechnology and Applied Biochemistry     Hybrid Journal   (Followers: 44)
Biotechnology and Bioengineering     Hybrid Journal   (Followers: 154)
Biotechnology and Bioprocess Engineering     Hybrid Journal   (Followers: 5)
Biotechnology and Genetic Engineering Reviews     Hybrid Journal   (Followers: 13)
Biotechnology and Health Sciences     Open Access   (Followers: 1)
Biotechnology and Molecular Biology Reviews     Open Access   (Followers: 2)
Biotechnology Annual Review     Full-text available via subscription   (Followers: 5)
Biotechnology for Biofuels     Open Access   (Followers: 10)
Biotechnology Frontier     Open Access   (Followers: 2)
Biotechnology Journal     Hybrid Journal   (Followers: 16)
Biotechnology Law Report     Hybrid Journal   (Followers: 4)
Biotechnology Letters     Hybrid Journal   (Followers: 34)
Biotechnology Progress     Hybrid Journal   (Followers: 40)
Biotechnology Reports     Open Access  
Biotechnology Research International     Open Access   (Followers: 1)
Biotechnology Techniques     Hybrid Journal   (Followers: 10)
Biotecnología Aplicada     Open Access  
Bioteknologi (Biotechnological Studies)     Open Access  
BIOTIK : Jurnal Ilmiah Biologi Teknologi dan Kependidikan     Open Access  
Biotribology     Hybrid Journal   (Followers: 1)
BMC Biotechnology     Open Access   (Followers: 16)
Cell Biology and Development     Open Access  
Chinese Journal of Agricultural Biotechnology     Full-text available via subscription   (Followers: 4)
Communications in Mathematical Biology and Neuroscience     Open Access  
Computational and Structural Biotechnology Journal     Open Access   (Followers: 2)
Computer Methods and Programs in Biomedicine     Hybrid Journal   (Followers: 8)
Copernican Letters     Open Access   (Followers: 1)
Critical Reviews in Biotechnology     Hybrid Journal   (Followers: 20)
Crop Breeding and Applied Biotechnology     Open Access   (Followers: 3)
Current Bionanotechnology     Hybrid Journal  
Current Biotechnology     Hybrid Journal   (Followers: 4)
Current Opinion in Biomedical Engineering     Hybrid Journal   (Followers: 1)
Current Opinion in Biotechnology     Hybrid Journal   (Followers: 56)
Current Pharmaceutical Biotechnology     Hybrid Journal   (Followers: 9)
Current Research in Bioinformatics     Open Access   (Followers: 12)
Current Trends in Biotechnology and Chemical Research     Open Access   (Followers: 3)
Current trends in Biotechnology and Pharmacy     Open Access   (Followers: 8)
EBioMedicine     Open Access  
Electronic Journal of Biotechnology     Open Access  
Entomologia Generalis     Full-text available via subscription  
Environmental Science : Processes & Impacts     Full-text available via subscription   (Followers: 4)
Experimental Biology and Medicine     Hybrid Journal   (Followers: 3)
Folia Medica Indonesiana     Open Access  
Food Bioscience     Hybrid Journal  
Food Biotechnology     Hybrid Journal   (Followers: 9)
Food Science and Biotechnology     Hybrid Journal   (Followers: 8)
Frontiers in Bioengineering and Biotechnology     Open Access   (Followers: 6)
Frontiers in Systems Biology     Open Access   (Followers: 2)
Fungal Biology and Biotechnology     Open Access   (Followers: 2)
GM Crops and Food: Biotechnology in Agriculture and the Food Chain     Full-text available via subscription   (Followers: 1)
GSTF Journal of BioSciences     Open Access  
HAYATI Journal of Biosciences     Open Access  
Horticulture, Environment, and Biotechnology     Hybrid Journal   (Followers: 11)
IEEE Transactions on Molecular, Biological and Multi-Scale Communications     Hybrid Journal   (Followers: 1)
IET Nanobiotechnology     Hybrid Journal   (Followers: 2)
IIOAB Letters     Open Access  
IN VIVO     Full-text available via subscription   (Followers: 4)
Indian Journal of Biotechnology (IJBT)     Open Access   (Followers: 2)
Indonesia Journal of Biomedical Science     Open Access   (Followers: 2)
Indonesian Journal of Biotechnology     Open Access   (Followers: 1)
Indonesian Journal of Medicine     Open Access  
Industrial Biotechnology     Hybrid Journal   (Followers: 17)
International Biomechanics     Open Access  
International Journal of Bioinformatics Research and Applications     Hybrid Journal   (Followers: 13)
International Journal of Biomechatronics and Biomedical Robotics     Hybrid Journal   (Followers: 4)
International Journal of Biomedical Research     Open Access   (Followers: 2)
International Journal of Biotechnology     Hybrid Journal   (Followers: 5)
International Journal of Biotechnology and Molecular Biology Research     Open Access   (Followers: 3)
International Journal of Biotechnology for Wellness Industries     Partially Free   (Followers: 1)
International Journal of Environment, Agriculture and Biotechnology     Open Access   (Followers: 5)
International Journal of Functional Informatics and Personalised Medicine     Hybrid Journal   (Followers: 4)
International Journal of Medicine and Biomedical Research     Open Access   (Followers: 1)
International Journal of Nanotechnology and Molecular Computation     Full-text available via subscription   (Followers: 3)
International Journal of Radiation Biology     Hybrid Journal   (Followers: 4)
Iranian Journal of Biotechnology     Open Access  
ISABB Journal of Biotechnology and Bioinformatics     Open Access  
Italian Journal of Food Science     Open Access   (Followers: 1)
JMIR Biomedical Engineering     Open Access  
Journal of Biometrics & Biostatistics     Open Access   (Followers: 3)
Journal of Bioterrorism & Biodefense     Open Access   (Followers: 6)
Journal of Petroleum & Environmental Biotechnology     Open Access   (Followers: 1)
Journal of Advanced Therapies and Medical Innovation Sciences     Open Access  
Journal of Advances in Biotechnology     Open Access   (Followers: 5)
Journal Of Agrobiotechnology     Open Access  
Journal of Analytical & Bioanalytical Techniques     Open Access   (Followers: 7)
Journal of Animal Science and Biotechnology     Open Access   (Followers: 4)
Journal of Applied Biomedicine     Open Access   (Followers: 2)
Journal of Applied Biotechnology     Open Access   (Followers: 2)
Journal of Applied Biotechnology Reports     Open Access   (Followers: 2)
Journal of Applied Mathematics & Bioinformatics     Open Access   (Followers: 5)
Journal of Biologically Active Products from Nature     Hybrid Journal   (Followers: 1)
Journal of Biomaterials and Nanobiotechnology     Open Access   (Followers: 6)
Journal of Biomedical Photonics & Engineering     Open Access  
Journal of Biomedical Practitioners     Open Access  
Journal of Bioprocess Engineering and Biorefinery     Full-text available via subscription  
Journal of Bioprocessing & Biotechniques     Open Access  
Journal of Biosecurity Biosafety and Biodefense Law     Hybrid Journal   (Followers: 3)
Journal of Biotechnology     Hybrid Journal   (Followers: 64)
Journal of Biotechnology and Strategic Health Research     Open Access  
Journal of Chemical and Biological Interfaces     Full-text available via subscription   (Followers: 1)
Journal of Chemical Technology & Biotechnology     Hybrid Journal   (Followers: 9)
Journal of Chitin and Chitosan Science     Full-text available via subscription   (Followers: 1)
Journal of Colloid Science and Biotechnology     Full-text available via subscription  
Journal of Commercial Biotechnology     Full-text available via subscription   (Followers: 6)
Journal of Crop Science and Biotechnology     Hybrid Journal   (Followers: 3)
Journal of Essential Oil Research     Hybrid Journal   (Followers: 2)
Journal of Experimental Biology     Full-text available via subscription   (Followers: 25)
Journal of Genetic Engineering and Biotechnology     Open Access   (Followers: 5)
Journal of Ginseng Research     Open Access  
Journal of Industrial Microbiology and Biotechnology     Hybrid Journal   (Followers: 17)
Journal of Integrative Bioinformatics     Open Access  
Journal of Medical Imaging and Health Informatics     Full-text available via subscription  
Journal of Molecular Biology and Biotechnology     Open Access  
Journal of Molecular Microbiology and Biotechnology     Full-text available via subscription   (Followers: 11)
Journal of Nano Education     Full-text available via subscription  
Journal of Nanobiotechnology     Open Access   (Followers: 4)
Journal of Nanofluids     Full-text available via subscription   (Followers: 1)
Journal of Organic and Biomolecular Simulations     Open Access  
Journal of Plant Biochemistry and Biotechnology     Hybrid Journal   (Followers: 4)
Journal of Science and Applications : Biomedicine     Open Access  
Journal of the Mechanical Behavior of Biomedical Materials     Hybrid Journal   (Followers: 12)
Journal of Trace Elements in Medicine and Biology     Hybrid Journal   (Followers: 1)
Journal of Tropical Microbiology and Biotechnology     Full-text available via subscription  
Journal of Yeast and Fungal Research     Open Access   (Followers: 1)
Marine Biotechnology     Hybrid Journal   (Followers: 4)
Meat Technology     Open Access  
Messenger     Full-text available via subscription  
Metabolic Engineering Communications     Open Access   (Followers: 4)
Metalloproteinases In Medicine     Open Access  
Microbial Biotechnology     Open Access   (Followers: 9)
MicroMedicine     Open Access   (Followers: 3)
Molecular and Cellular Biomedical Sciences     Open Access   (Followers: 1)
Molecular Biotechnology     Hybrid Journal   (Followers: 13)
Molecular Genetics and Metabolism Reports     Open Access   (Followers: 3)
Nanobiomedicine     Open Access  
Nanobiotechnology     Hybrid Journal   (Followers: 2)
Nanomaterials and Nanotechnology     Open Access  
Nanomedicine and Nanobiology     Full-text available via subscription  
Nanomedicine Research Journal     Open Access  

        1 2 | Last

Journal Cover
Australasian Biotechnology
Journal Prestige (SJR): 0.1
Number of Followers: 1  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 1036-7128
Published by RMIT Publishing Homepage  [399 journals]
  • Volume 27 Issue 1 - Specialist laboratory support
    • Abstract:
      360biolabs is an accredited (ISO 15189 and ISO / IEC 17025) contract research organisation (CRO) focused on providing specialist laboratory support for the preclinical and clinical development of our clients' therapeutics, vaccines and diagnostics.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Outstanding advancements in prosthetic design
    • Abstract:
      The University of Melbourne's biomedical engineers are changing lives with a world-first project.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Light sought, light found
    • Abstract:
      New knowledge acquired at the research-intensive University of Adelaide is being translated into life-changing, and life-saving, biomedical technology with a global impact.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Monash leading the way in medical engineering
    • Abstract:
      The Monash Institute of Medical Engineering (MIME) is perfectly placed to produce the next generation of medical technology.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Creating solutions in a diverse and challenging
           environment
    • Abstract:
      In a rapidly changing biomedical research and technology environment, researchers at The University of Western Australia (UWA) are at the forefront of discovering and developing solutions that meet medical challenges around the world.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Primordial ooze: The new frontier in the battle
           against antibiotic resistance
    • Abstract:
      Amid global concerns about the impacts of plastic on waterways and aquatic organisms, there is now evidence that antibiotics in wastewater streams are playing a significant role in the rise of antibiotic resistance.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Turn research and development expenditure into working
           capital
    • Abstract:
      When you are on the threshold of a major R and D milestone, nobody likes to raise capital at yesterday's equity valuation.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - AusBiotech corporate members
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Investing in the future of medical technology
    • Abstract:
      Do you have an innovative medical product or health-related technology and need more information on the next steps to commercialisation' Cook Medical Australia's new initiative is here to help!

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - MPR merges with prime to provide additional services
    • Abstract:
      One of Australia's leading firms in securing federal government research and development (R and D) tax incentives for the biotechnology and medtech industry, Melbourne's MPR Group, has merged with ASX-listed private wealth and business advisory firm Prime Financial Group.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Bosch Australia manufacturing solutions
    • Abstract: Croft, John
      Australian manufacturing is the subject of intense government and media scrutiny. Manufacturing now accounts for approximately six per cent of GDP, down from 12 per cent in the early 2000s. And this is before the impending cessation of high-volume vehicle manufacturing in Australia.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Strategic considerations for medical device companies
    • Abstract: Smith, Alistair
      Whatever your company's level of sophistication, having an appropriate intellectual property (IP) strategy can help to provide a competitive advantage. Unfortunately, IP is often viewed as an afterthought, and even when strong protection is obtained, if it does not align with your business strategy then it may be of little value.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Investor appetite for medtech companies remains strong
    • Abstract: Williamson, Kyahn
      While listed medical technology (medtech) companies in Australia are typically in the early stages of development - with market capitalisations below $300 million - Australia's investment market has a track record of supporting the commercialisation of some of the most successful medtech companies in the world, such as Cochlear and ResMed.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - US medical device investment a tough space
    • Abstract: Smith, Brigitte
      The current US environment for medical device investment is extremely tough, and there are very few signs that this will improve in the near term.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Stem cell-based models of human organ development and
           disease progression
    • Abstract: Musah, Samira
      The ability to propagate human cells ex vivo is the basis for significant advancements ranging from fundamental cell biology to medicine. Human pluripotent stem (PS) cells, which include human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, have generated substantial interest due to their capacity to self-renew indefinitely and differentiate into almost any specialised cell type. These unique properties make human PS cells a potentially unlimited supply of cells for several applications involving regenerative medicine, drug discovery, toxicology, disease modelling and understanding fundamental cell biology.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Cap-scaffolds tackle enduring medical problem
    • Abstract: Stynes, Gil
      All medical devices that pass through skin are plagued by infection at the skin interface. Such devices include intravenous lines, catheters, robotics, osseointegrated rods, bone-anchored hearing aids and tracheostomy tubes. Hence, one of the Holy Grails of biomaterials research over the last 40 years has been to create a robust skin-biomaterial interface. Skin fails to attach to implanted devices because of avulsion, infection and epidermal marsupialisation (a process whereby the epidermis tracks down and around implants).

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - 3d Nanofibre scaffolds for tissue engineering
    • Abstract: Mo, Xiumei
      Professor Xiumei Mo's research focuses on electrospinning techniques for creating 3D nanofibres that can be used in tissue rengeneration. She is a committee member of the Chinese Society for Biomaterials and the Biomedical Engineering Society's Biomaterials Branch. Australasian BioTechnology spoke with Professor Mo about her research.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Medical device regulatory reforms 2017: A period of
           significant change
    • Abstract: Skerritt, John
      The government response to the recent 'Expert Review of Medicines and Medical Devices Regulation (MMDR)' was released on 15 September 2016, with the majority of the recommendations accepted. Putting the reforms into practice will have implications for the regulation of medical devices in Australia.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Victoria: A state of Medtech innovation
    • Abstract: Wear, Andrew
      Victoria's technology sector is backed by outstanding talent, world-leading research institutes and infrastructure, and a government committed to supporting innovation.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Uncovering the secrets of elastin
    • Abstract: Weiss, Tony
      Elastin is common in the body, and provides tissue with elasticity. How this protein-based tissue was able to achieve its flexibility was a mystery to science until just last year, when Professor Tony Weiss, from the University of Sydney, and his team uncovered the molecule's unique movements.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Medtech for skin disease diagnosis - anywhere, any
           time
    • Abstract: Holt, Samuel
      SkinView is changing the way that diseases of the skin are diagnosed, starting with skin cancer and scabies. SkinView, which was one of two winners of the Murdoch Childrens Research Institute's Bytes4Health competition in November 2016, democratises the ability to capture medical-grade (dermatascopic and microscopic) images, and provides automated decision support/diagnosis, meaning that diseases such as skin cancer and scabies can be diagnosed anywhere, any time, at a fraction of traditional cost.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Maintaining Australia's competitive advantage in
           clinical trials
    • Abstract: MacLeman, Sue
      Australia is a world-class clinical research destination that attracts a significant level of clinical trial activity; however, the full details of this activity and the sources of its competitive advantage are not always well understood, even by industry participants.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Johnson and Johnson innovation partnering office @ qut
    • Abstract:
      When Queensland Premier Annastacia Palaszczuk attended the 2015 BIO International Convention in Philadelphia, an event dedicated to expanding the global biotechnology industry, she saw an opportunity to bring more resources back to her home state.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Adelaide's burgeoning medical devices industry
    • Abstract: Baccanti, Marco
      The global medical devices industry is changing rapidly, and Adelaide is well positioned to help companies take advantage of new opportunities.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Transforming health care: The connected ecosystem and
           digital health
    • Abstract: Le Grice, Bronwyn
      Being active in the healthcare space these days means frequently hearing the words 'digital health'. Over the past five to 10 years, the rate of digital disruption of all industries has been intense, with large, established services, such as hotels and taxis, being globally disrupted by technology platforms like Airbnb and Uber, by the growth of Bitcoin as an alternative currency, and by the advances in machine learning and artificial intelligence.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Do you know what your patients are saying about your
           treatment'
    • Abstract: Gallaher, Michelle
      Let me take a wild guess here: you have a Facebook profile and you look at it regularly. It won't surprise you to learn that you're not alone - half of all Australians access a social networking site at least once a day, and 95 per cent of Australians have a Facebook profile, accessing it roughly 32 times per week for 17-18 minutes each time1. This makes Facebook an immensely powerful vehicle through which to reach Australians.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - New AusBiotech members
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Index
    • Abstract: Hill, Joanna
      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Is your company investable from an IP perspective'
    • Abstract: McInnes, Rob
      As an experienced intellectual property lawyer with a life sciences background, I'm often called upon to carry out due diligence reviews on early-stage biotechnology and medical technology companies. While an investor will always have a high regard for a balanced scorecard of factors in making an investment decision, intellectual property (IP) issues loom large; after all, IP rights effectively make up the entire asset base of most early-stage life sciences companies.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Biotech CEOS invited to shape industry advocacy for
           the year ahead
    • Abstract: Phillips, Julie
      With the new year well underway, AusBiotech has pressed forward with the current Strategic Plan, which seeks to raise the profile of the Australian life sciences sector on both a national and a global scale. We are pleased to have launched the 'CEO Biotechnology Industry Position Survey 2017', which will be used to shape industry advocacy efforts in the year ahead.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - AusBiotech consolidates plan to draw together the
           entire life sciences ecosystem
    • Abstract: Cross, Glenn
      Last year, AusBiotech coordinated its first foray into combining industry and research events. We were proud to draw the entire life sciences ecosystem to the International BioFest 2016, the largest ever gathering in the Australian life sciences sector.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - AusBiotech board
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Industry news
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Antarctic floating seminar supports women in science
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - International BioFest 2016
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Biofest delegate report
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 27 Issue 1 - Innovation, collaboration and commercialisation
    • Abstract: Nabulsi, Samih
      When considering the challenges that researchers and innovators experience when presented with the opportunity to commercialise their life's work, two questions immediately come to mind: firstly, how do they navigate the pre-market pathways; and secondly, how do they choose the right partners'

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Ausbiotech CEO hands over leadership after stellar
           contribution
    • Abstract: Phillips, Julie
      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - AusBiotech board
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Inaugural CEO report
    • Abstract: Cross, Glenn
      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - A call to action
    • Abstract: MacLeman, Sue
      The growth of the Australian economy in the 21st century will depend on our ability to develop high-skill, value-adding industries that can compete in the global marketplace. In the medical technologies, pharmaceuticals and biotechnologies (MTP) sector, we are in a unique position to improve health on a global scale while doing so, but we must act now.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Industry news
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - International BioFest 2016
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Melbourne, Victoria: A leading global location for
           biotechnology
    • Abstract: Wear, Andrew
      Melbourne's strong focus on world-class biotechnology capabilities is helping cement its position as one of the world's leading locations for medical technology and pharmaceutical development. It has a long-established reputation for excellence in drug discovery, diagnostics, medical technologies, clinical trials and pharmaceutical manufacturing.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Australia Biotech Invest attracts global talent scouts
    • Abstract: Yoder, Stephen
      Bristol-Myers Squibb (BMS) is a diversified specialty biopharma company focused on serious diseases that have a persistently high unmet need, and the potential for transformative therapies that change standards of care. Members of the BMS Global team will be travelling to Australia for Australia Biotech Invest in October this year.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Exhibitors
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Partners and supporters
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Exhibitor profiles
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Partnering for world-class capability
    • Abstract: Savage, Paul; McLean, Keith
      It's a story all too familiar in our biotechnology scene: a small company, rich in innovation, struggles to transform its idea into a reality because of a lack of funding and connections. It can't afford to spend millions on laboratories or on a large research team, or years going it alone getting the science right.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Viral pathogen vaccines
    • Abstract: Young, Paul; Chappell, Keith; Watterson, Dan
      Professor Paul Young and his team from the Australian Infectious Diseases Research Centre at the University of Queensland, heads a laboratory with expertise in molecular virology. They are currently exploring the underlying mechanisms of severe disease caused by the dengue virus, and developing both therapeutic and vaccine control strategies for a range of viral pathogens.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - The business benefits of patient-centricity
    • Abstract: Perreault, Paul
      When patients have rare and serious diseases, they are usually well educated on their conditions. They have strong and considered opinions about what they want and need to help manage their condition, and improve their quality of life.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Improving 'last resort' antibiotics
    • Abstract: Roberts, Kade
      Antibiotic resistance has been identified by the World Health Organization (WHO) as one of the greatest threats facing human health globally. In a world without effective antibiotics, modern medical procedures that we take for granted, such as chemotherapy or simple surgery, will become too dangerous or simply impossible to undertake, due to the threat of untreatable bacterial infections.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Korea's sights set on Australia collaboration
    • Abstract: Cox, Eden
      Korea has many world-class industries, including the manufacture of semiconductors, smart phones, automobiles and home appliances, as well as shipbuilding. Its biotechnology industry, however, ranks far below the global level.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Establishing better links between industry and
           research
    • Abstract: Dromey, James; Singh, Lishia; Boag, Joanne
      In our experience, there is no such thing as 'one size fits all' when it comes to academic and industry collaborations. This is especially the case at the Murdoch Childrens Research Institute (MCRI), where research ranges from vaccines for infectious diseases in the developing world, to cutting-edge digital health technologies, treatments for rare genetic diseases, and regenerative medicine.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Microbial biosurfactants
    • Abstract: Razalli, Nurfarah Aina Mohamed; Rusly, Norazurin Syuhada; Zulaikha, Siti; Yusoff, Mohd; Awang, Mohd Syafiq; Zambry, Nor Syafirah; Ridhwan, Shahkillahwati Mohd; Noh, Nur Asshifa MD; Yahya, Ahmad RM
      Surfactants have a wide range of applications in many industries. Most are of chemical origin, which may make them hazardous to the environment, and interest has been increasing in finding biosurfactants as an alternative to chemical surfactants.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - 3D bioprinting: Can we create the structures in living
           cells'
    • Abstract: Beirne, Stephen; Yue, Zhilian; Wallace, Gordon G
      The assembly of structures to interact with living systems requires the ability to distribute multiple materials and different cell types in three dimensions. This assembly places a number of demands on the hardware required, and on the bioinks (liquid cell suspensions housed in printing cartridges).

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Nutrition, science and wellness
    • Abstract: Sali, Radek
      At a time when obesity figures are soaring and our public health system is straining to contain the pressures that come with associated diseases, we need to ensure that we increase our focus on wellness through nutrition. Movement and a mindful approach can also contribute to wellness, but here, I will focus on nutrition and science.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Protein by-products for meat quality
    • Abstract: Verbeek, Johan
      While the global love affair with meat continues, the underlying risks associated with meat consumption are often taken for granted. During slaughtering, meat quality is preserved by, among other things, preventing contact with faecal matter. To do this, the intestinal tract is sealed at both ends, preventing stomach and intestinal contents from coming into contact with meat.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Waves of change for Australia's marine biotech
    • Abstract: Zhang, Wei
      For Australia, marine biodiversity is a significant resource. Our sustainable development is inherently linked with the health of our oceans, which are facing major threats related to climate change, pollution and over-fishing. As the world's population continues to increase, so too does the demand for food, as well as employment, from the ocean's resources. The solution is to protect the marine environment while maximising its resources through a sustainable marine biotechnology industry that provides not only food, but economic prosperity, as well.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Australia's unique approach to biosimilars
    • Abstract: Morgan, Ric
      Biosimilars are generic biological products that are highly similar to - and for practical purposes, indistinguishable from - a product that already has approval from the relevant regulatory authority.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - New strategies to combat tuberculosis
    • Abstract: Schenk, Gerhard; Guddat, Luke W
      Tuberculosis (TB) is one of the most significant infectious diseases in the world today. According to the 2014 World Health Organization (WHO) annual report, there were an estimated 9.6 million new cases and 1.5 million fatalities in that year, and one-third of the world's population is now infected with the etiological agent 'Mycobacterium' tuberculosis. Due to successful control strategies in the 1980s, the current risk of Australians contracting this disease is low, but we are not totally immune to it, with around 1500 new cases diagnosed in Australia in 2014. Of more immediate concern is that TB remains a major threat to our nearest neighbours, including Papua New Guinea, Indonesia, Thailand and Vietnam.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Food, structure, bacteria and health
    • Abstract: Lockett, Trevor
      There's a revolution happening in health. Bacteria - long maligned as the arch nemeses of human health and wellbeing, to be destroyed at all costs - are now being recast in a different light.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - For a unified language to support life sciences
    • Abstract: Knispel, Roland; Niesz, Krisztian
      In cheminformatics, we witness the field of drug discovery changing rapidly in pursuit of developing new therapeutics. Scientists are confronted with an accelerated pace of change as vest amounts of novel scientific insights are pouring in. The response of the industry is diversification, for no one single organization is able to keep up with technological advances across the field, thus feeding the current trend of increased specialization and externalization. This in turn necessitates greater collaboration across multiple organizations, but on a higher level enables previously silo-ed research projects to be replaced by holistic approaches, which hold great promise to yield the medical treatments of tomorrow. Despite of best efforts to precisely engineer active compounds, current technologies rely on processes delivering stark heterogeneity of products. Detailed characterization is costly, hence often postponed until favorable compound profiles are reached, and sometimes not even possible to achieve. Large biomolecules, despite nowadays being in focus, are often not uniform enough, therefore it can be extremely difficult to accurately describe them. The problem is even more diverse, as finding the most appropriate and standard way of representation shall drive the success of registering such large structures into databases, searching those repositories as well as that of sharing data between partners who often do not speak the same language". So, it is clear, in order to reach date integrity and seamless communication between associates a unified language that bridges the gap between the worlds of small- and macromolecules is needed.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Adelaide's bio boom!
    • Abstract:
      At the University of Adelaide, we're tackling the world's grand challenges in new and innovative ways. Our global impact is reflected in the university's consistent ranking in the top-one per cent of universities in the world.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Partnerships are key to driving innovation in
           healthcare
    • Abstract:
      At Cook Medical Australia, our mission is simple; we are dedicated to bold leadership in pioneering innovative medical solutions to enhance patient care worldwide.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Hot-wiring biogas production
    • Abstract:
      Biogas (methane) production is an increasingly significant statistic on global energy markets, derived both from renewable resources such as food waste, animal waste and crops, and from fossil fuel resources such as coal and oil shale.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Sweet sorghum ethanol: The next crowning biofuel
    • Abstract: Zhang, Lei; Li, Shi-Zhong
      Mitigating climate change and greenhouse gas (GHG) emissions makes the development of renewable energies imperative around the world, even as oil prices continue to plunge. Many countries have devoted tremendous efforts to developing biofuels and solar power in order to shake off their dependence on fossil fuels. The efforts have sparked many exciting discussions about a sustainable future.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Microalgae products offer economic returns
    • Abstract: Vidal, Mary Ibarra
      Mary Ibarra Vidal, Master of Science candidate at the University of Calgary in Canada, is part of a team of researchers investigating ways to increase the production of high-value lipids and antioxidants through the cultivation of microalgae at biodiesel production plants, maximising the economic value of the whole process. Australasian BioTechnology speaks with Vidal about her research and its potential.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Biomass to transform the chemical industry
    • Abstract: Liden, Gunnar
      The advances that have been made in metabolic engineering of various host organisms today enables a growing number of chemical compounds to be produced from sugars, rather than petroleum. Some of these products, such as propanediol, and lactic and succinic acid, are reaching commercial-scale production.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - The patentability of diagnostic methods
    • Abstract: Tyacke, Nicholas; Mallon, Eliza; Italiano, Louis; Shandler, Brett
      United States courts have recently held in the Sequenom case that a claimed diagnostic method was not patentable. Sequenom has recently commenced proceedings in Australia, asserting infringement of similar diagnostic method claims. Will Australian courts reach the same conclusion regarding patentability as the United States courts, or will the divergence between United States and Australian law regarding patentability, and the Australian High Court Myriad decision, lead to a different outcome'

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Post-grant developments in europe
    • Abstract: Harding, Charles; Wroe, Stephanie
      The European Patent Office (EPO) has introduced new procedures to reduce the duration of straightforward opposition cases from between 19 and 27 months, to just 15 months. To achieve this, the EPO has reduced the internal handling time from 11 months to five months, and shortened deadlines for the parties. At the same time, the EPO has given parties more time to react to the summons to oral proceedings and to prepare for oral proceedings.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Game of zones
    • Abstract:
      Steve Jasper is a PhD candidate who is halfway through his degree, studying the effects of time zone differences on performance, and using the Australian biotech sector as the setting for the research.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Turning lawn into jet fuel
    • Abstract: Khor, Way C; Andersen, Stephen J; Vervaeren, Han; Rabaey, Korneel
      What do you think of when you see grass' A cow' Football' Grass-type Pok mon' Nowadays, it is also possible to relate grass to a jet or, more precisely, jet fuel.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Getting rubber to hit the road: Funding research for
           impact
    • Abstract: Chambers, Noel
      Opportunities for the community to benefit from biomedical innovations arise through complex translational and commercialisation pathways. While Australian researchers rank highly on international measures of research quality, their ability to translate research into medical innovations and form collaborations ranks far below its potential.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Collaboration to increase 'shots on goal'
    • Abstract:
      The University of Queensland has established a new venture to translate and commercialise its biomedical research, with the goal of developing life-changing therapies.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Med tech in South Australia is thriving and growing:
           Here's why
    • Abstract:
      There is an incredible power in medical technologies. Devices like the cochlear implant and prosthetic limbs transform the lives of individuals and create energising ripples through families and communities. Each product is the result of a specific medical challenge being addressed through innovation.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - The new era of clinical research
    • Abstract:
      Every day, clinical trials advance our understanding of how disease affects the human body and how medicines, medical devices and diagnostic tools relieve suffering and save lives. Thanks to advancements in technology, results of this research are more readily available than ever before, decreasing product-development time and enabling therapeutic products to reach the market sooner.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - AusBiotech corporate members
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - New members
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - Index
    • Abstract: Hill, Joanna
      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 3 - The shock of the new: Translating the potential of
           regenerative medicine technologies
    • Abstract:
      More than a decade ago, scientists around the world confidently predicted that stem cell research would revolutionise medicine. Enabling legislation followed the technology, as did a dramatic increase in funding that paralleled the public's impatient expectations. It's only within the past couple of years that we have finally started to see the vanguard of this regenerative movement begin to be realised - what began as a trickle of clinical trials has now become a steady stream around the globe.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Industry news
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Ausbiotech board
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Chair and CEO report
    • Abstract: Lavelle, Anna; Phillips, Julie
      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - AusMedtech 2016: Australia's Medtech conference
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Immunotherapy to treat AFL star's Melanoma
    • Abstract: Heppell, Giulia
      Hawthorn star player Jarryd Roughead has commenced 12 months of immunotherapy to treat cancer.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - GM and the community: A call to action
    • Abstract: Neely, Rob
      Over the last decade, we have seen a tectonic shift in public opinion in two critical areas of agricultural biotechnology. On the one hand, the public has been convinced that genetic modification (GM) of plants is a bad thing, while on the other, it applauds the efforts of fast-food retailers and supermarkets to eliminate antibiotics from the food chain due to fears of antimicrobial-resistant superbugs.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - 100 years old and just getting started
    • Abstract:
      CSL was established in 1916 by the Australian Government to ensure that the isolated nation had reliable access to life-saving biological products. One hundred years later, it has become Australia's largest and most successful biotechnology company, with substantial in-house, onshore translational research and development capabilities.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Gene genie: The judicial revolution in biotech IP
    • Abstract: Rimmer, Matthew
      Over the past few years, there have been some dramatic developments in intellectual property (IP) and biotechnology. In landmark rulings in gene patents in superior courts in the United States and Australia, as well as a significant settlement in Canada, the judiciary has sought to draw tighter boundaries around what can be protected as an invention under patent law. The superior courts have been keen to emphasise that mere products of nature, abstract ideas, and intellectual information cannot be protected under patent law. This has caused some consternation among the commercial providers of medical diagnostics, the pharmaceutical industry and the biotechnology sector. The judicial revolution in IP and biotechnology will have an impact in agriculture, medicine, health care and clean technologies.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Index
    • Abstract: Hill, Joanna
      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - New member profiles
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Technology convergence: The impact of digital
           technology on treatment and patient interaction
    • Abstract: Petris, Anita; Macleod, Phoebe; Dromey, James
      The use of digital technology in health is becoming ubiquitous. The rapid rise in wearables, along with the growing consumer interest in managing and tracking one's health, is now a major worldwide trend. This is changing how consumers access and interact with health care, and is leading to greater participation in the control and management of their own health, as highlighted in Eric Topol's book 'The Patient Will See You Now: The Future of Medicine is in Your Hands'. In this article, we outline how digital technology is affecting treatment and patient interaction, and how it is opening up new models of research and clinical care.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Helping clinicians to develop innovative medical
           devices
    • Abstract: Lockwood, Olivia
      The SA Biomedical Research and Teaching (R and T) team members are the go-to gadget gurus, using cutting-edge technology to find innovative solutions to problems faced by clinicians and medical researchers within SA Health and Flinders University, School of Medicine. The R and T team has mechanical, electronic, software and biomedical expertise, accumulated during more than 30 years creating medical devices, from original concept and prototyping, through to clinical trial.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Cancer immunotherapy comes of age (finally!)
    • Abstract: Nisbet, Ian
      'Immuno-oncology' is the current buzzword in cancer treatment, with drugs like pembrolizumab (KEYTRUDA) and nivolumab (Opdivo) providing exciting new treatment options for an expanding range of tumour types, including melanoma and lung cancer. The ability to activate the immune system to kill cancer cells has become a focus area for oncology drug discovery and development.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Immunotherapy overview
    • PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Shifting gears: How the changing landscape of
           Australian manufacturing can benefit the medical techology industry
    • Abstract: Roberts, Peter
      For medical technology industries, there may be a silver lining to the dark cloud that is hanging over Australia's manufacturing sector, but it does not make up for the damage being wrought on the country's industrial capacity.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Outpacing cancer: An interview with Josie Downey, MSD
    • Abstract: Downey, Josie
      Cancer immunotherapy is a breakthrough that is providing much hope for patients with the greatest needs. MSD is advancing a broad and fast-growing clinical development program for its immunotherapy medicine KEYTRUDA.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Combination therapies with immune checkpoint
           inhibitors
    • Abstract: Lopez, Jamie
      Despite decades of work that has contributed to our fundamental understanding of cancer immunology, it has only been in recent years that we have seen this translate into effective cancer treatments. The unprecedented success of immune checkpoint inhibitors, such as PD-1/ PD-L1 and CTLA-4 antibodies, has ushered in a new era of cancer treatments, with improved response rates compared with standard-of-care chemotherapeutics. These therapies work by boosting the host's natural cancer immune surveillance. While initial clinical trials with immunotherapeutic drugs have focused on cancers with a high mutational load and higher immune infiltrates, such as melanoma and lung cancer, many other cancers are now being actively assessed, such as renal, breast, head and neck, and haematological malignancies.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Next-generation DNA vaccine targets HPV tumour cells
    • Abstract: Cox, Eden
      In 2006, Professor Ian Frazer won the Australian of the Year award for his research that led to the Gardasil vaccine, which provides immunity from some human papillomavirus (HPV) strains and associated cervical cancers. Working with Admedus Ltd (ASX: AHZ), Prof Frazer is now developing a next-generation DNA vaccine technology, which, if successful, will target and clear HPV-positive tumour cells in people who are already infected.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
  • Volume 26 Issue 2 - Bosch Australia manufacturing solutions
    • Abstract: Croft, John
      Australian manufacturing is the subject of intense government and media scrutiny. Manufacturing now accounts for approximately six per cent of GDP from 12 per cent in the early 2000s. And this is before the impending cessation of high-volume vehicle manufacturing in Australia.

      PubDate: Thu, 2 Nov 2017 11:47:42 GMT
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 54.166.203.17
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-